BIOLASE to Participate in the Benchmark Discovery One-on-One Investor Conference on December 1, 2022 in New York

Rhea-AI Summary

BIOLASE, Inc. (NASDAQ: BIOL) is set to participate in the 11th Annual Benchmark Discovery One-on-One Investor Conference on December 1, 2022, in New York City. CEO John Beaver and CFO Jennifer Bright will conduct individual meetings with investors and analysts at the conference. The company is a leader in dental laser technology, having sold over 43,300 systems since 1998 in more than 80 countries. BIOLASE's innovative products feature 302 patented technologies designed to enhance dental procedures.

LAKE FOREST, Calif., Nov. 14, 2022 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced it has been invited to participate in the 11^th Annual Benchmark Discovery One-on-One Investor Conference taking place December 1, 2022 in New York City. President and Chief Executive Office, John Beaver, and Chief Financial Officer, Jennifer Bright, will host one-on-one meetings with investors and analysts during the event.

To schedule a one-on-one investor meeting with BIOLASE management, please contact BIOLASE's investor relations firm, EVC Group, LLC at tkehrli@evcgroup.com.  

About BIOLASE

BIOLASE is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine. BIOLASE's products advance the practice of dentistry and medicine for patients and healthcare professionals. BIOLASE's proprietary laser products incorporate approximately 302 patented and 28 patent-pending technologies designed to provide biologically and clinically superior performance with less pain and faster recovery times. BIOLASE's innovative products provide cutting-edge technology at competitive prices to deliver superior results for dentists and patients. BIOLASE's principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. BIOLASE has sold over 43,300 laser systems from 1998 through December 31, 2021 in over 80 countries around the world. Laser products under development address BIOLASE's core dental market and other adjacent medical and consumer applications.

For updates and information on Waterlase iPlus^®, Waterlase Express^™, and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, Instagram at www.instagram.com/waterlase_laserdentistry, and LinkedIn at www.linkedin.com/company/biolase.

BIOLASE^®, Waterlase^® and Waterlase iPlus^® are registered trademarks of BIOLASE, Inc.

Contacts:
EVC Group, Inc.
Michael Polyviou/Todd Kehrli
(732) 232-6914
mpolyviou@evcgroup.com; tkehrli@evcgroup.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/biolase-to-participate-in-the-benchmark-discovery-one-on-one-investor-conference-on-december-1-2022-in-new-york-301676633.html

SOURCE BIOLASE, Inc.

FAQ

What is the date of BIOLASE's participation in the investor conference?

BIOLASE will participate in the investor conference on December 1, 2022.

Who from BIOLASE will be present at the Benchmark Discovery Conference?

BIOLASE's CEO John Beaver and CFO Jennifer Bright will represent the company at the conference.

Where is the 11th Annual Benchmark Discovery Conference taking place?

The conference is taking place in New York City.

What is the ticker symbol for BIOLASE?

The ticker symbol for BIOLASE is BIOL.

How many laser systems has BIOLASE sold worldwide?

BIOLASE has sold over 43,300 laser systems in more than 80 countries.